$TMO · Thermo Fisher Scientific Inc.

On September 26, 2026, Karen S. Lynch, a director of Thermo Fisher Scientific Inc., reported a change in beneficial ownership on a Form 4 filing. The filing discloses the acquisition of 46.3 phantom stock units under the company’s Deferred Compensation Plan for Directors. These units were credited to her account at a price of $675.00 per unit, reflecting the closing stock price for the quarter end, as part of the quarterly deferral of director retainers.

The phantom stock units are convertible into common stock on a one-for-one basis. Under the plan, the units are distributable as shares only upon cessation of director service for any reason or upon a change of control. After the reported transaction, Lynch beneficially owned 398.7 phantom stock units directly. The filing does not report any sale or open-market purchase of common stock.